INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $246,021 | -27.2% | 4,723 | -11.5% | 0.15% | -25.5% |
| Q2 2023 | $337,876 | +6.8% | 5,336 | -8.6% | 0.20% | +14.9% |
| Q1 2023 | $316,236 | +4.2% | 5,840 | +1.9% | 0.17% | +10.1% |
| Q4 2022 | $303,390 | +49.5% | 5,733 | +31.6% | 0.16% | +95.1% |
| Q3 2022 | $203,000 | -17.1% | 4,357 | +1.4% | 0.08% | -11.0% |
| Q2 2022 | $245,000 | -61.6% | 4,296 | -58.8% | 0.09% | -68.2% |
| Q1 2022 | $638,000 | +17.1% | 10,419 | 0.0% | 0.29% | +38.8% |
| Q4 2021 | $545,000 | +36.6% | 10,419 | -2.7% | 0.21% | +17.0% |
| Q3 2021 | $399,000 | -16.4% | 10,703 | -8.4% | 0.18% | -10.2% |
| Q2 2021 | $477,000 | -43.2% | 11,679 | -52.8% | 0.20% | -44.8% |
| Q1 2021 | $840,000 | +9.7% | 24,764 | +2.8% | 0.36% | +11.6% |
| Q4 2020 | $766,000 | +94.9% | 24,085 | +57.4% | 0.32% | +54.4% |
| Q3 2020 | $393,000 | -11.9% | 15,303 | -12.0% | 0.21% | -2.4% |
| Q2 2020 | $446,000 | +3.5% | 17,392 | -38.0% | 0.21% | +19.2% |
| Q1 2020 | $431,000 | -60.9% | 28,050 | -12.7% | 0.18% | -1.7% |
| Q4 2019 | $1,103,000 | +630.5% | 32,139 | +59.1% | 0.18% | +500.0% |
| Q3 2019 | $151,000 | -45.5% | 20,197 | -5.3% | 0.03% | -48.3% |
| Q2 2019 | $277,000 | +20.4% | 21,322 | +12.9% | 0.06% | -88.1% |
| Q1 2019 | $230,000 | -6.5% | 18,878 | -12.7% | 0.49% | +1064.3% |
| Q4 2018 | $246,000 | -49.1% | 21,613 | -2.9% | 0.04% | -16.0% |
| Q3 2018 | $483,000 | -28.4% | 22,258 | -41.7% | 0.05% | -91.6% |
| Q2 2018 | $675,000 | -36.0% | 38,174 | -23.8% | 0.60% | -34.8% |
| Q1 2018 | $1,054,000 | +214.6% | 50,088 | +116.8% | 0.92% | +117.9% |
| Q4 2017 | $335,000 | -30.6% | 23,102 | -24.5% | 0.42% | +546.2% |
| Q3 2017 | $483,000 | +40.0% | 30,600 | +10.1% | 0.06% | +27.5% |
| Q2 2017 | $345,000 | +15.8% | 27,801 | +51.7% | 0.05% | -3.8% |
| Q1 2017 | $298,000 | +19.2% | 18,329 | +10.6% | 0.05% | -29.3% |
| Q4 2016 | $250,000 | +155.1% | 16,572 | +157.2% | 0.08% | +59.6% |
| Q3 2016 | $98,000 | -60.8% | 6,443 | 0.0% | 0.05% | -74.7% |
| Q2 2016 | $250,000 | – | 6,443 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |